IRD

3.9902.21%
JS

James S. J. Manuso

Independent Chairman of the Board

Dr. James S. J. Manuso, also known as Jim, Ph.D., MBA, serves as Chief Transaction Advisor & Director and served as Chair of Regulatory Affairs at Targazyme, Inc. He served as Director of Targazyme, Inc. until January 2023 and served as it's Member of Advisory Board since January 2023. He serves as Independent Chairman of the Board at Tuhura Biosciences, Inc. since October 18, 2024 and has been its Director since November 2022. He has been Chief Business Officer of Symbiontics, Inc. Dr. Manuso serves as Independent Director of Opus Genetics, Inc. (formerly known as Ocuphire Pharma, Inc.) since November 2020. Prior to that, he served on the Board of Private Ocuphire from January 2019 until November 2020. Since 2014, Dr. Manuso has served as chairman and chief executive officer of Talfinium Investments, Inc., an investment entity and financial consultancy. Since 2018, Dr. Manuso has served as managing member of Laurelside LLC, a family office, which he founded. Dr. Manuso served as Vice Chairman, Chief Executive Officer and President at RespireRx Pharmaceuticals Inc. (formerly known as Cortex Pharmaceuticals, Inc.) since August 18, 2015 till September 30, 2018. Dr. Manuso served as Chairman and Chief Executive Officer of Astex Pharmaceuticals, Inc. from January 1, 2004 to October 2013. He served as the President of Astex Pharmaceuticals, Inc. from January 1, 2004 to July 2011. He served as the Chief Executive Officer of Astex Pharmaceuticals, Inc. from September 2003 to December 2003. He served as Consultant of Astex Pharmaceuticals, Inc. since September 5, 2003. Dr. Manuso Co-founded Regalen Inc. and served as President and Chief Executive Officer until September 5, 2003. He co-founded Manuso, Alexander & Associates, Inc. and served as its President since 1992. He co-founded PrimeTech Partners in 1998 and served as its General Partner from 1998 to 2002. Dr. Manuso was a Managing General Partner of The Channel Group LLC, an international life sciences corporate advisory firm. From 1984 to 1992, he developed and consulted to biotechnology companies and managed family investments. From 1974 to 1983, Dr. Manuso served as an Officer of The Equitable Companies, serving in the capacities of Acting Medical Director and Director of Health Care Planning and Development. He served as the Vice President of the Greater San Francisco Bay Area Leukemia & Lymphoma Society. Dr. Manuso serves as Vice Chairman of Symbiontics, Inc. and ZyStor Therapeutics, Inc. He served as Chairman and Director at EuroGen, Ltd. He served as Vice Chairman of Quark Biotech, Inc. He serves as a Director of KineMed, Inc. He serves as a Director of Regalen Inc. and Biotechnology Industry Organization. He served as a Director of Merrion Pharmaceuticals Limited from July 2006 to September 2008. He served on the Board of Private Ocuphire from January 2019 until November 2020. He served as a Director of Cellectar Biosciences, Inc. since August 2007 until November 08, 2013. He served as a Director of Galenica Pharmaceuticals, Symbiontics, Inc. and the greater San Francisco Bay Area Chapter of the Leukemia and Lymphoma Society. Dr. Manuso also served on the boards of Inflazyme Pharmaceuticals, Inc., Novelos Therapeutics, Inc. (2008 – 2011), Montigen Pharmaceuticals, Inc., Quark Pharmaceuticals, Inc. (2003 – 2007), Galenica Pharmaceuticals, Inc. and Supratek Pharma (2003 – 2004), Inc. Dr. Manuso served as a Director at Astex Pharmaceuticals, Inc. since February 2001 until 2013. He is the author of over 30 chapters, articles and books on topics including health care cost containment and biotechnology company management. He was Vice Chair and Head of M&A at H.C. Wainwright & Co., LLC, an investment banking company from 2013 and was Chairman, President & CEO at SuperGen, Inc., a public hematology-oncology pharmaceuticals developer with profitable commercial operations from 2003 until 2011. He was Director of Merrion Pharmaceuticals plc (2006 – 2008), Inflazyme Pharmaceuticals, Inc. (2002 – 2005),Biotechnology Innovation Organization (2011 – 2013), Montigen Pharmaceuticals, Inc. (2011 – 2012), EuroGen, Ltd. (2003 – 2008), Symbiontics, Inc. (2003 – 2006) and Galenica Pharmaceuticals, Inc. (2001 – 2003). He taught and lectured at Columbia, NYU, Georgetown University, Polytechnic University and Waseda University (Japan). Dr. Manuso holds an B.A. in Economics and Chemistry from New York University, a Ph.D in Experimental Psychophysiology and Genetics from the Graduate Faculty of The New School University, a Certificate in Health Systems Management from Harvard Business School and an Executive MBA from Columbia Business School.

Positions